CMPI Checkmate Pharmaceuticals Inc.

13.71
-0.39  -3%
Previous Close 14.1
Open 14.1
52 Week Low 8.61
52 Week High 23.1
Market Cap $295,457,999
Shares 21,550,547
Float 13,650,941
Enterprise Value $169,755,294
Volume 5,480
Av. Daily Volume 28,393
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
CMP-001 and pembrolizumab
Melanoma
Phase 1b
Phase 1b
Phase 1b data presented at SITC meeting November 2020. 17.5% partial response rate for monotherapy, 28% for combo.
CMP-001 and pembrolizumab
Head and neck squamous cell carcinoma (HNSCC)
Phase 2
Phase 2
Phase 2 trial planned late 2020/early 2021.
CMP-001 and nivolumab
Melanoma
Phase 2
Phase 2
Phase 2 trial is ongoing. Interim data noted pathological Complete Response, or pCR, rate of 62%.

Latest News

  1. Robert F. Dolski appointed as Chief Financial Officer

    Katherine Eade appointed as General Counsel

    CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Robert F. Dolski as Chief Financial Officer. Mr. Dolski brings to Checkmate more than 20 years of diversified management experience as a life sciences financial executive driving the strategy, planning, execution, and financing of private and public biopharmaceutical companies.

    In addition to Mr. Dolski's appointment, Checkmate recently strengthened…

    Robert F. Dolski appointed as Chief Financial Officer

    Katherine Eade appointed as General Counsel

    CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Robert F. Dolski as Chief Financial Officer. Mr. Dolski brings to Checkmate more than 20 years of diversified management experience as a life sciences financial executive driving the strategy, planning, execution, and financing of private and public biopharmaceutical companies.

    In addition to Mr. Dolski's appointment, Checkmate recently strengthened their leadership team by naming Katherine Eade, a seasoned legal and business executive with proven expertise in advising public life sciences companies, as General Counsel.

    "Rob's validated track record and broad range of industry experience driving the financial strategy for various biopharmaceutical companies will play a crucial role in the growth of our company as we advance our lead program, CMP-001, into advanced clinical development," said Barry Labinger, President and Chief Executive Officer of Checkmate. "We are thrilled to have both Rob and Katherine join our team to help lead Checkmate in extending the impact of immunotherapy for patients living with cancer."

    "CMP-001 has a rapidly growing body of clinical data demonstrating its potential as a new treatment option to improve response in combination with checkpoint inhibitors," said Mr. Dolski. "I am excited to join Checkmate's team of accomplished industry veterans and look forward to supporting Checkmate in advancing its business priorities."

    Mr. Dolski joins Checkmate from Akcea Therapeutics where he served as Vice President, Finance. In this role, he oversaw accounting operations, SEC reporting, financial planning and treasury activities supporting the development and global commercialization of several rare disease programs. Previously, he was Vice President, Head of Financial Planning & Analysis for Moderna Therapeutics, and he was Senior Director, Finance at Forum Pharmaceuticals, Inc., a late-stage private equity funded pharmaceutical company focused on neuro-degenerative diseases. He served as Vice President, Finance and Treasury at Human Genome Sciences, Inc., which was acquired by GlaxoSmithKline. Mr. Dolski started his career in the biopharma industry at Amgen, Inc. holding various financial roles. He earned an MBA from The Wharton School and a BS in civil engineering and strategic management from the University of Pennsylvania.

    Katherine Eade is an experienced legal and business executive with more than 19 years of experience advising public companies on significant corporate transactions, corporate governance and capital markets, including 12 years in the life sciences industry. She currently serves as a member of the board of directors of Harvard Bioscience. Before joining Checkmate, Ms. Eade served as Vice President, Strategic Commercial Affairs at Align Technology, and she previously served as the Director, M&A Law and Transactions for Corning Incorporated and Division Counsel for Corning's Life Sciences and Pharmaceutical Technologies divisions. She began her legal career at Cleary Gottlieb, a leading international law firm, and she served as a law clerk for Judge Morton I. Greenberg of the U.S. Court of Appeals for the Third Circuit. She received a JD, cum laude, from Harvard Law School and a BA in government, summa cum laude, from Cornell University.

    About Checkmate Pharmaceuticals

    Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate's product candidate, CMP-001, is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate is available at www.checkmatepharma.com.

    Availability of Other Information About Checkmate Pharmaceuticals

    Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com), and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

    Forward Looking Statements

    Various statements in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. These statements include those regarding our product candidate, including its development and therapeutic potential and the advancement of our clinical and preclinical pipeline; expectations regarding the results and analysis of data; and expectations regarding the timing, initiation, implementation and success of its planned clinical trials for CMP-001, and the benefits and related implications of current and future partnerships and/or collaborations.  Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials, the results from clinical trials, including the fact that positive results from a trial may not necessarily be predictive of the results of future or ongoing clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and obtaining, maintaining and protecting our intellectual property. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 dated November 13, 2020, as filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act 1933, as amended, which is available on the Securities and Exchange Commission's website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. 



    Investor Contact
    Kleem Chaudhary 
    Chief Business Officer 
    
    
    Media Contact
    Karen Sharma 
    MacDougall 
    781-235-3060 
    

    Primary Logo

    View Full Article Hide Full Article
  2. CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate Pharmaceuticals"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced it has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE:BMY) to evaluate the combination of Checkmate Pharmaceuticals' CMP-001, a Toll-like receptor 9 (TLR9) agonist, and Bristol Myers Squibb's Opdivo® (nivolumab), a PD-1 blocking antibody.

    The companies will collaborate on two trials: (a) a single arm Phase 2 study of CMP-001 in combination with nivolumab in subjects with unresectable or metastatic melanoma that is…

    CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate Pharmaceuticals"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced it has entered into a clinical collaboration agreement with Bristol Myers Squibb (NYSE:BMY) to evaluate the combination of Checkmate Pharmaceuticals' CMP-001, a Toll-like receptor 9 (TLR9) agonist, and Bristol Myers Squibb's Opdivo® (nivolumab), a PD-1 blocking antibody.

    The companies will collaborate on two trials: (a) a single arm Phase 2 study of CMP-001 in combination with nivolumab in subjects with unresectable or metastatic melanoma that is refractory to PD-1 blockade as monotherapy or in combination with other therapies, and (b) a randomized Phase 2 study of first-line CMP-001 in combination with nivolumab compared to nivolumab monotherapy in subjects with unresectable or metastatic melanoma. For both trials, under the terms of the agreement, Checkmate Pharmaceuticals will be the sponsor and Bristol Myers Squibb will supply nivolumab.

    "This collaboration between Checkmate Pharmaceuticals and Bristol Myers Squibb underscores our mutual dedication to advancing the impact of immunotherapy for the benefit of patients living with melanoma and other types of cancer," said Barry Labinger, President and Chief Executive Officer of Checkmate Pharmaceuticals. "We believe that CMP-001 in combination with Opdivo offers promise for patients and we are pleased to be working together with Bristol Myers Squibb on this important pursuit."

    Opdivo® is a registered trademark of Bristol Myers Squibb.

    About Checkmate Pharmaceuticals

    Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals' product candidate, CMP-001, is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate Pharmaceuticals is available at www.checkmatepharma.com.

    Availability of Other Information About Checkmate Pharmaceuticals

    Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com), and on social media (Twitter and Linkedin), including but not limited to: investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

    Forward Looking Statements

    Various statements in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. These statements include those regarding our product candidate, including its development and therapeutic potential and the advancement of our clinical and preclinical pipeline; expectations regarding the results and analysis of data; and expectations regarding the timing, initiation, implementation and success of its planned clinical trials for CMP-001, and the benefits and related implications of current and future partnerships and/or collaborations.  Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials, the results from clinical trials, including the fact that positive results from a trial may not necessarily be predictive of the results of future or ongoing clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and obtaining, maintaining and protecting our intellectual property. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 dated November 13, 2020, as filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act 1933, as amended, which is available on the Securities and Exchange Commission's website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.



    Investor Contact
    Kleem Chaudhary 
    Chief Business Officer 
     
    
    Media Contact
    Karen Sharma 
    MacDougall 
    781-235-3060 
     

    Primary Logo

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced third quarter 2020 financial results and provided an update on recent progress.

    "We are enthusiastic as we advance CMP-001 toward registration in melanoma and expand toward potential proof of concept in additional indications," said Barry Labinger, Chief Executive Officer. "We remain on track to initiate key new clinical trials by late 2020/early 2021 as planned."

    Recent Progress

    • During SITC's 35th Anniversary Annual Meeting, three new data presentations were given…

    CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced third quarter 2020 financial results and provided an update on recent progress.

    "We are enthusiastic as we advance CMP-001 toward registration in melanoma and expand toward potential proof of concept in additional indications," said Barry Labinger, Chief Executive Officer. "We remain on track to initiate key new clinical trials by late 2020/early 2021 as planned."

    Recent Progress

    • During SITC's 35th Anniversary Annual Meeting, three new data presentations were given evaluating CMP-001, Checkmate's advanced generation Toll-like receptor 9 (TLR9) agonist. These data continue to demonstrate the clinical activity of CMP-001 in combination with anti-PD-1 antibodies in patients with melanoma.
    • Checkmate is actively engaging with potential clinical sites and remains on track to initiate three Phase 2 trials combining CMP-001 with PD-1 blockade by late 2020/early 2021 for the treatment of:
      • First-line head and neck cancer
      • Anti-PD-1 refractory melanoma
      • First-line metastatic or unresectable melanoma

    Third Quarter 2020 Financial Results

    • Cash and cash equivalents: Cash and cash equivalents were $137.3 million as of September 30, 2020.
    • Research and development expenses (R&D): R&D expenses were $6.7 million for the quarter ended September 30, 2020, compared to $5.1 million for the quarter ended September 30, 2019. The increase was primarily attributable to increased headcount and clinical trial expenses in connection with increased patient enrollment in the ongoing clinical trials of CMP-001 and preparations for the initiation of planned additional clinical trials of CMP-001. These increases were partially offset by a decrease in contract manufacturing costs.
    • General and administration expenses (G&A): G&A expenses were $3.2 million for the quarter ended September 30, 2020, compared to $1.2 million for the quarter ended September 30, 2019. The increase was primarily attributable to increases in personnel and other operating expenses incurred in connection with Checkmate beginning to operate as a publicly-traded company.
    • Net loss and comprehensive loss: Net loss and comprehensive loss was $9.8 million for the quarter ended September 30, 2020, compared to $6.2 million for the quarter ended September 30, 2019.

    About Checkmate Pharmaceuticals



    Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate's product candidate, CMP-001, is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate is available at www.checkmatepharma.com.

    Availability of Other Information About Checkmate

    Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com), and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate posts on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

    Forward Looking Statements

    Various statements in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. These statements include those regarding our product candidate, including its development and therapeutic potential and the advancement of our clinical and preclinical pipeline; expectations regarding the results and analysis of data; and expectations regarding the timing, initiation, implementation and success of its planned clinical trials for CMP-001.  Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials, positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and obtaining, maintaining and protecting its intellectual property. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 dated September 18, 2020, as filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act 1933, as amended, which is available on the Securities and Exchange Commission's website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.



    CHECKMATE PHARMACEUTICALS, INC.

    SUMMARY STATEMENTS OF OPERATIONS

    (Unaudited)

    (In thousands)

     Three Months Ended 

    September 30,
     Nine Months Ended

    September 30,
      2020   2019   2020   2019 
    Operating expenses:       
    Research and development$6,673  $5,076  $19,462  $17,126 
    General and administrative 3,160   1,208   6,465   3,365 
    Total operating expenses 9,833   6,284   25,927   20,491 
    Loss from operations (9,833)  (6,284)  (25,927)  (20,491)
    Other income (expense), net:       
    Interest income 4   43   32   160 
    Change in fair value of convertible loan notes       (83)   
    Total other income (expense), net 4   43   (51)  160 
    Net loss and comprehensive loss$(9,829) $(6,241) $(25,978) $(20,331)
                    

    CHECKMATE PHARMACEUTICALS, INC.

    SUMMARY BALANCE SHEETS

    (In thousands)

    (Unaudited)

      September 30,  December 31,
       2020   2019 
          
    Cash and cash equivalents $         137,340  $4,185 
    Other current assets               6,725                 941 
    Total assets $         144,065  $         5,126 
          
    Current liabilities $              8,860  $           5,634 
         Total liabilities $                8,860  $         5,634 
          
    Series A redeemable convertible preferred stock                          —            32,482 
    Series B redeemable convertible preferred stock                          —            64,446 
          
    Total stockholders' equity (deficit)                   135,205   (97,436)
    Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) $           144,065  $         5,126 
    Investor Contact
    Kleem Chaudhary
    Chief Business Officer
    
    
    Media Contact
    Karen Sharma
    MacDougall 
    781-235-3060
    

    Primary Logo

    View Full Article Hide Full Article
  4. CMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma in ongoing trial

    Encouraging new data on pathological responses and 1-year RFS with neoadjuvant CMP-001 and nivolumab in resectable Stage IIIB/C/D melanoma

    CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of new data from two ongoing clinical trials evaluating CMP-001, Checkmate's Toll-like receptor 9 (TLR9) agonist, in combination with the anti-PD-1 antibodies pembrolizumab (KEYTRUDA®…

    CMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma in ongoing trial

    Encouraging new data on pathological responses and 1-year RFS with neoadjuvant CMP-001 and nivolumab in resectable Stage IIIB/C/D melanoma

    CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of new data from two ongoing clinical trials evaluating CMP-001, Checkmate's Toll-like receptor 9 (TLR9) agonist, in combination with the anti-PD-1 antibodies pembrolizumab (KEYTRUDA®) or nivolumab (OPDIVO®), in patients with melanoma.

    "CMP-001 continues to demonstrate clinical benefit, in combination with anti-PD-1 antibodies, with an ORR of 23.5% and median duration of response of 19.9 months in patients with anti-PD-1 refractory melanoma," said Barry Labinger, President and Chief Executive Officer of Checkmate. "We are also encouraged by the maturing data in the anti-PD-1 naïve neoadjuvant study, which has demonstrated a 70% pathological response rate and 1-year relapse free survival of 90% in patients with a pathologic response."

    Intratumoral injection of CMP-001, a Toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma (Abstract #: 579; NCT02680184)

    In the SITC 2020 Virtual Press Conference, November 9, between 7:45am-9:00am ET, and in the Virtual Poster Hall, November 11-14, 2020 between 9:00am-5:00pm ET, Dr. Mohammed Milhem, Chief, Section of Oncology, and Clinical Professor of Internal Medicine, University of Iowa Healthcare, presents updated data from an ongoing Checkmate-sponsored clinical trial of CMP-001 in combination with pembrolizumab or as a monotherapy.

    Key highlights from these clinical data as of the data cut-off of September 30, 2020 include:

    CMP-001 in combination with pembrolizumab

    • In patients treated with CMP-001 PS20 0.01% in combination with pembrolizumab, the best ORR by RECIST v1.1 was 23.5% (23/98), including 7 complete responses and 16 partial responses, and 27.6% (27/98) including patients with responses after initial progressive disease.
    • The Kaplan Meier estimate for median duration of response across all patients was 19.9 months for both RECIST v1.1 responders and RECIST v1.1 responders plus post-progressive disease responders.
    • The mean regression in injected and non-injected target lesions was similar in responding patients.
    • Most treatment related adverse events (TRAEs) were Grade 1 or 2 and included flu-like symptoms, including chills, fever, fatigue, nausea, vomiting, and headache, and injection site pain. The most common treatment-related Grade 3 or 4 adverse events were hypotension (6.3%) and hypertension (5.0%). No Grade 5 treatment-related adverse events were reported.

    CMP-001 monotherapy

    • Of the 40 patients treated with CMP-001 monotherapy, 7 patients (17.5%) achieved a partial response by RECIST v1.1, and the median duration of response was 5.6 months.
    • Most treatment-related adverse events were Grade 1 or 2 and included flu-like symptoms including chills, fever, nausea, fatigue, and headache. The only treatment-related Grade 3 adverse event in more than 1 patient was hypotension (n=2, 5.0%). No Grade 4 or 5 treatment-related adverse events were reported.

    "The response rate, duration of response, and adverse event profile are encouraging given that 93% of the patients had progressive disease as the last response to anti-PD-1 antibodies at study entry," said Dr. Milhem. "We need new treatment approaches for patients who progress after anti-PD-1 antibodies, and I'm excited to move this regimen forward into a potentially registrational study in patients with confirmed disease progression on PD-1 blockade."

    Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High-Risk Resectable Melanoma (Neo-C-Nivo) (Abstract #: 612; NCT03618641)

    In a Virtual Oral Presentation on Wednesday, November 11, 2020 at 5:30pm ET, Dr. Diwakar Davar, Assistant Professor of Medicine at the University of Pittsburgh School of Medicine, presents data from an investigator-sponsored trial evaluating neoadjuvant treatment with CMP-001 in combination with nivolumab in patients with Stage IIIB/C/D Melanoma.

    Key highlights from these clinical data included:

    • 30 patients were evaluable for efficacy per protocol.
      • Pathological responses were observed in 70% of patients, and the primary outcome measure of major pathological response rate was 60%. The response breakdown was as follows:
        • Pathological Complete Response (pCR = 15/30; 50%)
        • Pathological Major Response (pMR = 3/30; 10%)
        • Pathological Partial Response (pPR = 3/30; 10%)
    • The median RFS has not been reached.
      • 1-year RFS was 89% in patients with major pathological response (pCR and pMR) and 90% in patients with any pathological response (pCR, pMR, and pPR).
    • 31 patients were evaluable for safety per protocol.
      • CMP-001 in combination with nivolumab was generally well-tolerated with an acute toxicity profile consisting predominantly of Grade 1/2 TRAEs. The only treatment-related Grade 3 adverse event in more than 1 patient was hypertension (n=3, 9.7%). No Grade 4/5 TRAEs were reported.
      • There were no dose limiting toxicities or delays in surgery related to neoadjuvant treatment.
    • Response was associated with evidence of intratumoral and peripheral immune activation.

    "The pathological response rate in this study is among the highest reported for treatment that includes a PD-1 blocking antibody in neoadjuvant treatment of Stage III melanoma, and compares favorably with the reported data for neoadjuvant PD-1/CTLA-4 Opacin-Neo," said Dr. Davar. "We are encouraged by the relapse free survival, and I'm particularly excited by our data demonstrating the activation of pDCs and infiltration of T cells in many of the responding tumors, which provides further support for the mechanism of action of CMP-001."

    Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1-6 mouse models of hepatocellular carcinoma (Abstract #: 418)

    In the Virtual Poster Hall, November 11-14, 2020 between 9:00am-5:00pm ET, Dr. Arthur M. Krieg, Founder and Chief Scientific Officer of Checkmate Pharmaceuticals, presents data from a preclinical study of CMP-001 plus PD-1 blocking antibody in mouse models of hepatocellular carcinoma.

    In orthotopic mouse models of HCC, the antitumor activity of intravenous CMP-001 was greater than PD-1 blockade and comparable to sorafenib. CMP-001 intravenous was more active than CMP-001 subcutaneous in this model, consistent with increased liver exposure with intravenous infusion. CMP-001 intravenous may be a promising treatment option to explore in future clinical research for patients with primary or metastatic liver cancers.

    About CMP-001

    CMP-001 comprises a virus-like particle utilizing a CpG-A oligonucleotide. It is designed to trigger the body's innate immune system via TLR9 and infiltrate the tumor microenvironment by the subsequent induction of both innate and adaptive anti-tumor immune responses. Checkmate believes CMP-001 is the only compound utilizing a CpG-A class TLR9 agonist in clinical development. For information on CMP-001 trials that are currently recruiting patients, please visit www.clinicaltrials.gov.

    About Checkmate Pharmaceuticals

    Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer. Checkmate's product candidate, CMP-001, is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. Checkmate's goal is to leverage its proprietary technology to discover, develop and commercialize transformative treatments to fight cancer. Information regarding Checkmate is available at www.checkmatepharma.com.

    Availability of Other Information About Checkmate

    Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com), and on social media (Twitter and Linkedin), including but not limited to: investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate posts on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

    Forward Looking Statements

    Various statements in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. These statements include those regarding our product candidate, including its development and therapeutic potential and the advancement of our clinical and preclinical pipeline; expectations regarding the results and analysis of data.  Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials; the risk that positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; the risk that data updates and interim results may not be predictive of future results; the impact of the ongoing COVID-19 pandemic on our business, operations, clinical trials, clinical supply and plans; the risks inherent in the drug development process; the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing; and obtaining, maintaining and protecting our intellectual property. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our quarterly report on Form 10-Q for the quarter ended June 30, 2020, as filed with the U.S. Securities and Exchange Commission (SEC), as well as subsequent filings and reports filed with the SEC, which are available on the SEC's website at www.sec.gov.

    All registered trademarks are the property of their respective owners.

    Investor Contact
    Kleem Chaudhary 
    Chief Business Officer 
    
    
    Media Contact
    Karen Sharma 
    MacDougall 
    781-235-3060 
    

    Primary Logo

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the upcoming Jefferies Virtual London Healthcare Conference. The presentation is scheduled for 6:45 – 7:15am ET on Tuesday, November 17, 2020 and will be webcast.

    A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Checkmate website. An archived copy of the webcast will be available on the Checkmate website for approximately 45 days after the event.

    About Checkmate Pharmaceuticals

    CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the upcoming Jefferies Virtual London Healthcare Conference. The presentation is scheduled for 6:45 – 7:15am ET on Tuesday, November 17, 2020 and will be webcast.

    A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Checkmate website. An archived copy of the webcast will be available on the Checkmate website for approximately 45 days after the event.

    About Checkmate Pharmaceuticals



    Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer. Checkmate's product candidate, CMP-001, is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. Checkmate's goal is to leverage its proprietary technology to discover, develop and commercialize transformative treatments to fight cancer. Information regarding Checkmate is available at www.checkmatepharma.com

    Forward Looking Statements

    Various statements in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. These statements include those regarding our product candidate, including its development and therapeutic potential, the advancement of our clinical and preclinical pipeline and expectations regarding the results and analysis of data.  Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and obtaining, maintaining and protecting its intellectual property. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our prospectus dated August 6, 2020, as filed with the Securities and Exchange Commission ("SEC") pursuant to Rule 424(b) under the Securities Act 1933, as amended, which is available on the SEC's website at www.sec.gov, and in the Company's subsequent filings with the SEC.

    Investor Contact
    Kleem Chaudhary
    Chief Business Officer
    
    
    Media Contact
    Karen Sharma
    MacDougall 
    781-235-3060
    

    Primary Logo

    View Full Article Hide Full Article
View All Checkmate Pharmaceuticals Inc. News